Cytomegalovirus (CMV) Infections – Pipeline Assessment and Market Forecasts to 2019...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.1.3 Risk Factors 13
3.2 Epidemiology 13
3.2.1 CMV Prevalence in General Population 13
3.2.2 CMV Prevalence in At-Risk Populations 14
3.3 Symptoms 15
3.4 Diagnosis and Referral 15
3.4.1 CMV DNA PCR 15
3.4.2 Conventional viral cultures of tissue biopsy or bodily fluids 15
3.4.3 Shell vial culture 16
3.4.4 CMV serology 16
3.4.5 Histopathologic exam with in-situ hybridization 16
3.4.6 Retinal examination using an indirect ophthalmoscope 16
3.4.7 PP65 antigenemia test 16
3.4.8 Referral 17
3.5 Treatment Guidelines 18
3.6 Disease Management 19
4 Competitive Assessment 21
4.1 Overview 21
4.2 Strategic Competitor Assessment 21
4.3 Product Profiles for the Major Marketed Products 25
4.3.1 Ganciclovir sodium 25
4.3.2 Valcyte (valganciclovir) 27
4.3.3 CMV-IGIV 29
4.3.4 Cidofovir 30
4.3.5 Foscarnet 31
4.3.6 Summary of Marketed Drugs 33
5 Opportunity and Unmet Need 34
5.1 Overview 34
5.2 Unmet Needs 37
5.2.1 Unmet Need: Safety 37
5.2.2 Unmet Need: Efficacy 37
5.2.3 Unmet Need: Prophylactic Vaccine 37
5.2.4 Unmet Need: Therapeutic Vaccine 37
5.2.5 Unmet Need: Patient Compliance 38
5.2.6 Unmet Need: Patient Awareness 38
5.2.7 Unmet Need: Physician Education 38
5.2.8 Unmet Need: Early Diagnosis of CMV in Pregnant Women and Transplant Patients 39
5.2.9 Unmet Need: Drug Resistance with Currently Available Antiviral Drugs 39
5.3 Opportunities 39
5.3.1 Opportunity: Vaccine Development Remains a Major Opportunity 39
5.3.2 Opportunity: Addressing Patient Compliance for Long-Term Therapy 39
5.3.3 Opportunity: Generating Physician and Patient Awareness 40
6 Pipeline Assessment 41
6.1 Overview 41
6.2 Strategic Pipeline Assessment 41
6.3 Pipeline Analysis by Phase of Development 42
6.3.1 Phase III Clinical Pipeline 42
6.3.2 Phase II Clinical Pipeline 42
6.3.3 Phase I Pipeline 43
6.3.4 Pre-clinical Pipeline 43
6.3.5 Discovery Pipeline 44
6.4 Pipeline by Mechanism of Action 44
6.5 Technology Trends Analytical Framework 46
6.6 Most Promising Drugs in Clinical Development 48
6.7 Most Promising Drug Profiles 49
6.7.1 TransVax 49
6.7.2 AIC246 52
6.7.3 Maribavir 54
6.7.4 CMX001 56
7 Clinical Trial Mapping 58
7.1 Clinical Trials by Region/Country (US, 5EU and Japan) 58
7.2 Clinical Trials by Phase 59
7.3 Clinical Trials by Trial Status 59
7.4 Clinical Trials by Prominent Sponsors 60
8 Current and Future Players 61
8.1 Trends in Corporate Strategy 61
8.2 Company Profiles 62
8.2.1 F. Hoffmann-La Roche (Roche) 62
8.2.2 Vical 63
8.2.3 AiCuris 65
8.2.4 ViroPharma 66
8.2.5 Chimerix 67
9 Licensing and Partnership Deals 69
9.1 Overview 69
9.2 Key Deals and Alliances in the Past 18 Months 69
10 Market Outlook 70
10.1 Seven Major Markets Overview 70
10.2 Regional Analysis 73
10.2.1 US 73
10.2.2 France 74
10.2.3 Germany 75
10.2.4 Italy 76
10.2.5 Spain 77
10.2.6 UK 77
10.2.7 Japan 78
10.3 Key Events 79
10.4 Drivers and Barriers 79
10.4.1 Drivers for the CMV Infections Market 80
10.4.2 Barriers for the CMV Infections Market 80
11 Appendix 82
11.1 Bibliography 82
11.2 Abbreviations 86
11.3 Methodology 87
11.3.1 Coverage 87
11.3.2 Secondary Research 87
11.3.3 Forecasting Methodology 88
11.3.4 Primary Research 91
11.3.5 Expert Panel Validation 92
11.4 Physicians and Specialists Included in this Study 92
11.5 About the Authors 92
11.5.1 Analysts 92
11.6 About GlobalData 93
11.7 Contact Us 93
11.8 Disclaimer 93